Financial Performance - The company's operating revenue for 2022 was RMB 364,080.05 million, representing a 10.35% increase compared to RMB 329,942.97 million in 2021[18]. - The net profit attributable to shareholders of the listed company reached RMB 40,756.91 million, a 33.52% increase from RMB 30,525.82 million in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 37,391.08 million, up 24.42% from RMB 30,053.38 million in 2021[18]. - The net cash flow from operating activities was RMB 21,586.53 million, a decrease of 12.93% compared to RMB 24,792.11 million in 2021[18]. - As of the end of 2022, the total assets amounted to RMB 343,765.93 million, reflecting a 20.36% increase from RMB 285,607.70 million at the end of 2021[18]. - The net assets attributable to shareholders of the listed company were RMB 186,286.16 million, which is a 25.79% increase from RMB 148,087.77 million in the previous year[18]. - The basic earnings per share (EPS) increased to RMB 2.68, up 33.33% from RMB 2.01 in 2021[19]. - The weighted average return on equity rose to 25.27%, an increase of 2.26 percentage points from 2021[19]. - The company reported a significant increase in pharmaceutical industrial revenue, which grew by 11.73% year-on-year[29]. - The company's pharmaceutical industrial revenue was 1.88 billion CNY, up 11.73% year-on-year, while pharmaceutical commercial revenue was 1.72 billion CNY, increasing by 8.52%[63]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 10 per 10 shares, totaling RMB 153,398,600 to all shareholders[4]. - In 2022, the company distributed cash dividends of 123,341,374 RMB, which accounted for 37.79% of the net profit attributable to shareholders[173]. - The total cash distribution, including share buybacks, amounted to 161,673,912.26 RMB, representing 49.56% of the net profit attributable to shareholders[174]. - The company has implemented a cash dividend policy, distributing a total of 630 million RMB in cash dividends over the past 14 years, reflecting a commitment to shareholder returns[172]. Risk Management - The company has not reported any significant risks that could materially affect its operations during the reporting period[6]. - The company emphasizes the importance of risk management in its operations, addressing various risks including industry policy, raw material, market competition, and R&D risks[6]. - The company faces risks from policy changes in the heavily regulated pharmaceutical industry, which could impact its operations[134]. - The company is actively working to diversify its product structure to mitigate risks associated with raw material price fluctuations[135]. - In 2022, the company faced risks related to raw material supply due to market demand and environmental factors, leading to an increase in traditional Chinese medicine material prices[136]. Research and Development - The company launched 26 new drug R&D projects in 2022, including 3 new pediatric formulations and received 1 clinical trial approval[35]. - The company has 40 ongoing research projects, including 26 new drug development projects and 8 secondary development projects[105]. - The total R&D investment for the year was RMB 72.66 million, with RMB 71.99 million classified as expense and RMB 0.68 million as capitalized[106]. - The company is focusing on the development of TCM new drugs, with ongoing projects including a new type of TCM granule and a pediatric cough syrup[52]. - The company is actively pursuing patent protections for its innovative drug formulations and preparation methods[100]. Market Expansion and Strategy - The company is focusing on innovation and quality as key drivers for future growth amidst a challenging market environment[29]. - The company plans to expand its market presence by opening a second TCM clinic in Hankou in March 2023[37]. - The company is exploring market expansion opportunities in Southeast Asia, targeting a 15% market share within the next three years[148]. - Strategic acquisitions are being considered to bolster the company's portfolio and enhance operational capabilities[148]. - The company is expanding its market share in hospitals and retail sectors while accelerating brand development and innovation in health products[137]. Corporate Governance - The company held four shareholder meetings in 2022, reviewing 23 proposals, ensuring compliance with legal and regulatory requirements[140]. - The board of directors convened 12 meetings in 2022, reviewing 57 proposals, and ensuring timely decision-making on significant matters[141]. - The audit committee held six meetings in 2022 to oversee financial reporting and compliance, enhancing the company's internal control[141]. - The supervisory board conducted eight meetings in 2022, focusing on compliance and risk management to safeguard the company's operations[143]. - The company has established strict insider information management protocols, ensuring no insider trading incidents occurred during the reporting period[143]. Environmental Responsibility - The company has invested 5.6 million CNY in environmental protection during the reporting period[186]. - The total emissions of key pollutants from the subsidiary were within the permitted limits, with COD emissions at 22.2 tons per year[189]. - The company has achieved compliance with environmental standards, with all monitored pollutants meeting regulatory limits[189]. - The company has established a comprehensive sewage treatment plant with a daily processing capacity of 800 tons, operating 24 hours a day[191]. - The company has implemented carbon reduction measures despite not being included in the national carbon market quota management list[199]. Employee Development - The company has established a comprehensive employee training system, conducting an MBA training program for 72 personnel in 2022[171]. - The company has committed to continuous talent development, focusing on cultivating high-level management talent through various training programs[171]. - The company has a performance-based salary system, adjusting salaries annually based on individual performance and company operating conditions[170]. - The company has initiated a stock incentive plan, granting 369,600 restricted shares to eligible employees in 2022[178]. - The workforce includes 165 R&D personnel, making up 21.8% of the total staff, indicating a strong focus on innovation[83].

证券代码：600976 证券简称：健民集团 公告编号：2023-003 健民药业集团股份有限公司 关于召开 2022 年度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 09 日(星期四)至 03 月 15 日(星期三)16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 （ir.jmjt@whjm.com）进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 健民药业集团股份有限公司（以下简称"公司"）将于 2023 年 03 月 15 日发 布公司 2022 年年度报告及其相关公告，为便于广大投资者更全面深入地了解公 司 2022 年年度经营成果、财务状况，公司计划于 2023 年 03 月 16 日 ...

健民药业集团股份有限公司 2022 年第三季度报告 单位：元 币种：人民币 证券代码：600976 证券简称：健民集团 健民药业集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|------------------|----------------- ...

2022 年半年度报告 公司代码：600976 公司简称：健民集团 健民药业集团股份有限公司 2022 年半年度报告 1 / 195 2022 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实性、准确性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别 和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人何勤、主管会计工作负责人程朝阳及会计机构负责人（会计主 管人员）张英声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司半年度不进行利润分配或资本公积金转增股本。 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质 承诺，敬请投资者注意投资风险。 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性 和完整性 否 十、 重大风险提示 报 ...

证券代码：600976 证券简称：健民集团 公告编号：2022-034 健民药业集团股份有限公司 关于参加 2022 年湖北辖区上市公司投资者集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2022 年 6 月 16 日（星期四）14：00-16：00 会议召开地点："全景• 路演天下"（http://rs.p5w.net）网络平台 会议召开方式：网络文字互动 预征集投资者提问的相关安排：投资者可在 2022 年 6 月 15 日（星期三） 16:00 前 登 录 http://rs.p5w.net/zj/ " 问 题 征 集 专 题 " 或 通 过 公 司 邮 箱 （ir.jmjt@whjm.com）进行提问，公司将在本次活动上就投资者普遍关注的问题 进行回答。 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办2022年湖北辖区上市公司投资者集体接待日暨2021年度业绩说明会活动的通 知》，健民药业集团股份有限公司（以下简称"公司"）将于 20 ...

2022 年第一季度报告 单位：元 币种：人民币 证券代码：600976 证券简称：健民集团 健民药业集团股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|-----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 917,942,461.38 ...

Financial Performance - The company's operating revenue for 2021 was RMB 3,278,183,640.34, representing a year-on-year increase of 33.48%[24]. - The net profit attributable to shareholders for 2021 was RMB 324,736,841.19, a significant increase of 119.73% compared to the previous year[24]. - The net cash flow from operating activities increased by 106.46% to RMB 259,183,455.41, driven by growth in sales scale[24]. - The total assets at the end of 2021 were RMB 2,825,602,235.14, reflecting a year-on-year increase of 16.90%[24]. - The net assets attributable to shareholders at the end of 2021 were RMB 1,561,213,992.01, up 18.55% from the previous year[24]. - Basic earnings per share (EPS) for 2021 was CNY 2.13, up 121.88% from CNY 0.96 in 2020[27]. - The weighted average return on equity (ROE) increased to 21.86%, up 10.13 percentage points from 11.73% in 2020[27]. - The company reported a quarterly revenue of CNY 672.16 million in Q4 2021, with a decline in net profit attributable to shareholders to CNY 67.64 million due to year-end impairment provisions[28]. Revenue Segmentation - Revenue from the pharmaceutical manufacturing segment grew by 43.92% year-on-year, while pharmaceutical commerce revenue increased by 24.48%[24]. - The pharmaceutical industry segment generated CNY 1,682.25 million in revenue, up from CNY 1,174.35 million in 2020[40]. - In 2021, the company achieved a 43.92% year-on-year growth in pharmaceutical industrial revenue, with OTC sales increasing by 51.28% and Rx sales growing by 36.23%[41]. - The company reported a decrease of 31.02% in revenue from other business segments[24]. - The pharmaceutical commercial segment reached 1,588.1850 million RMB, growing by 24.48%[59]. Product Development and R&D - The company initiated 25 new drug research projects in 2021, including 5 pediatric formulations, and received 1 new drug certificate[45]. - The company launched new products such as "Zhuo Bei Gao" children's growth milk powder and expanded its e-commerce business[45]. - The company has 39 ongoing research projects, including 25 new drug development projects, 10 secondary development projects, and 4 health food projects[110]. - The company is committed to enhancing its R&D capabilities and expanding its product pipeline in the future[119]. - The company plans to increase R&D investment and improve the conversion rate of research outcomes in response to the rapid inclusion of innovative drugs in the medical insurance system[54]. Market Strategy and Expansion - The company plans to focus on product development and marketing strategies to enhance competitiveness in response to industry changes[39]. - The company aims to maintain rapid growth in operating performance and asset quality through refined management and cost control[39]. - The company aims to enhance its position in the national supply chain by focusing on talent development and core technology breakthroughs, addressing critical issues in the pharmaceutical industry[49]. - The company is committed to high-quality innovation and increasing R&D investment in response to national policies encouraging innovation and high-end manufacturing[49]. - The company is actively exploring innovative business models, including traditional Chinese medicine services and health tourism[143]. Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[9]. - The company faces risks related to product concentration, with three key products accounting for over 50% of industrial revenue, necessitating a focus on product diversification[144]. - The company faces risks from fluctuations in raw material prices, particularly traditional Chinese medicine materials, which are affected by natural conditions and market supply-demand dynamics[147]. - The implementation of centralized procurement for traditional Chinese medicine by the National Medical Insurance Administration in 2022 poses a risk of product price declines[147]. - New drug development involves high investment and risk, with potential challenges in clinical efficacy and market acceptance[147]. Corporate Governance and Management - The company held 6 shareholder meetings and 15 board meetings, reviewing a total of 84 proposals[151]. - The company disclosed 146 pieces of information in 2021, including 4 regular reports and 77 temporary announcements, achieving a B rating from the Shanghai Stock Exchange for information disclosure[154]. - The company has established a management system for insider information, ensuring compliance and confidentiality[154]. - The company maintains open communication with investors through various channels, enhancing investor relations management[154]. - The total pre-tax remuneration for the chairman, He Qin, was CNY 1.0136 million, with a significant increase in shareholding from 0 to 318,720 shares due to equity incentives[162]. Future Outlook - The company provided a forward guidance of 10% revenue growth for the next fiscal year, projecting revenues of $1.32 billion[167]. - The company plans to invest $50 million in new technology to improve operational efficiency over the next two years[167]. - The company anticipates significant growth in the domestic pharmaceutical market due to increasing healthcare awareness and an aging population[139]. - The company plans to enhance market forecasting and strategic procurement to mitigate raw material supply risks[147]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[171].

2021 年第三季度报告 单位：元 币种：人民币 证券代码：600976 证券简称：健民集团 健民药业集团股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|------------------|------------------------- ...

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,792,722,536.20, representing a 74.50% increase compared to CNY 1,027,323,574.04 in the same period last year[26]. - The net profit attributable to shareholders of the listed company reached CNY 167,152,775.88, a significant increase of 192.24% from CNY 57,196,566.32 in the previous year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 158,928,248.12, up 203.40% from CNY 52,382,254.32 year-on-year[26]. - The net cash flow from operating activities was CNY 77,575,100.99, which is a 176.09% increase compared to CNY 28,097,696.31 in the same period last year[26]. - The company's basic earnings per share (EPS) for the first half of the year is CNY 1.10, a 197.30% increase compared to CNY 0.37 in the same period last year[28]. - The weighted average return on equity (ROE) rose to 12.1%, an increase of 7.45 percentage points from 4.65% in the previous year[28]. - The basic earnings per share after deducting non-recurring gains and losses is CNY 1.04, reflecting a 205.88% increase from CNY 0.34 in the same period last year[28]. Revenue Growth - The company's revenue grew by 74.50% year-on-year, with pharmaceutical manufacturing revenue up 73.24% and pharmaceutical commerce revenue up 75.76%[28]. - The net profit attributable to shareholders increased by 192.24% year-on-year, primarily driven by increased revenue from key products such as Longmu Zhuanggu Granules[28]. - Longmu Bone Strengthening Granules sold over 20 million bags during the reporting period, significantly contributing to revenue growth[64]. Asset and Equity Changes - The net assets attributable to shareholders of the listed company at the end of the reporting period were CNY 1,392,573,679.47, reflecting a 5.75% increase from CNY 1,316,907,795.03 at the end of the previous year[26]. - The total assets of the company amounted to CNY 2,584,719,184.14, which is a 6.93% increase compared to CNY 2,417,176,831.31 at the end of the previous year[26]. - The company's equity attributable to shareholders increased to approximately $1.39 billion, up from $1.32 billion, reflecting a growth of about 5.7%[172]. Cost and Expense Management - Operating costs increased to ¥1,044,479,932.20, reflecting a 73.8% rise from ¥600,966,639.75 in the previous year[69]. - The pharmaceutical segment's revenue grew by 69.50%, with a gross margin increase of 2.69 percentage points to 72.64%[72]. - The company is focusing on optimizing production processes and enhancing quality while controlling costs, with a reported cost growth of 61.24% being lower than revenue growth[69]. Research and Development - The company has 30 new drug projects under research, which may face high investment and risk challenges[95]. - R&D efforts are progressing steadily, with several pediatric formulation projects completing critical testing phases and new drug clinical research advancing as planned[66]. - Research and development expenses for the first half of 2021 were ¥16,010,356.99, slightly up from ¥15,633,456.53 in the previous year, indicating a growth of about 2.4%[182]. Environmental Management - The company has established an environmental management system that includes regular monitoring and reporting of pollutant discharge concentrations and volumes[117]. - The company reported that all emissions from Yekai Thai Pharmaceutical are within the permitted limits, with no violations of environmental regulations during the reporting period[118]. - The company has committed to continuous improvement in environmental management and energy conservation efforts[117]. Market Position and Strategy - The company is positioned to benefit from ongoing reforms in the pharmaceutical industry, including the integration of medical insurance and healthcare systems[37]. - The company is actively expanding its market presence through new product development and marketing strategies, including the launch of OTC products like Bian Tong Capsules[66]. - The company focuses on pediatric, gynecological, and geriatric treatment areas, offering nearly 500 varieties of products[55]. Shareholder Information - The total number of shares held by directors and executives increased significantly due to stock incentives, with notable increases for key individuals such as He Qin and Wang Jun[159]. - The largest shareholder, Huali Pharmaceutical Group Co., Ltd., holds 38,484,073 shares, accounting for 25.09% of the total shares[151]. - The company has repurchased a total of 1,432,001 shares, representing 0.93% of the total share capital, with a total expenditure of approximately 39.99 million RMB[141].

证券代码：600976 证券简称：健民集团 公告编号：2021-043 健民药业集团股份有限公司 关于参加湖北上市公司 2021 年度投资者网上集体接 待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2021 年 6 月 24 日（星期四）15：30-17：00 会议召开地点："全景• 路演天下"（http://rs.p5w.net）网络平台 会议召开方式：网络文字互动 会议问题征集：投资者可在 2021 年 6 月 23 日（星期三）16:00 前将关 注的问题发送至公司电子邮箱（ir.jmjt@whjm.com），公司将在湖北上市公司 2021 年度投资者网上集体接待日活动中就投资者普遍关注的问题进行回答。 为进一步加强与广大投资者的互动交流，根据湖北省上市公司协会《关于举 办"真诚沟通，互信共赢"湖北上市公司 2021 年度投资者网上集体接待日活动 的通知》，健民药业集团股份有限公司（以下简称"公司"）将于 2021 年 6 月 24 日下午 15：30-17：00 参 ...